PENTICTON, BC /CNW/ – XCO Tech Inc. (XCO) today announced it is receiving advisory services and funding of up to $1M from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) over… Read More
VANCOUVER, BC– NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced… Read More
Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW:FSE) announced the launch of a new clinical research program that will evaluate the use of the drug Ifenprodil (NP-120) in treating pancreatic cancer. The announcement followed the… Read More
VANCOUVER, BC – Incisive Genetics Inc. (“IG”), a privately held biotech company specializing in the research and development of a novel non-viral delivery platform for targeted CRISPR-based gene therapies, announced… Read More
Vancouver, BC– iCo Therapeutics Inc. (“iCo” or the “Company”) (TSXV: iCo) (OTCQB: iCoTF) is pleased to announce that the Company has received formal conditional approval from the TSX Venture Exchange… Read More
